Polymyositis Market Insight

DelveInsight’s ‘Polymyositis—Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Polymyositis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

The Polymyositis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Polymyositis market Size from 2018 to 2030, segmented by seven major markets. The report also covers the current Polymyositis treatment practice/algorithm and unmet medical needs to curate the best opportunities and assess the underlying market potential.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Polymyositis: Disease Understanding and Treatment Algorithm

Polymyositis Overview

Polymyositis (PM) is a chronic autoimmune disease, and it is a subtype of rare muscle diseases called idiopathic inflammatory myopathies (IIM). Other IIM subtypes include dermatomyositis (DM), inclusion body myositis (IBM), and necrotizing myopathy.

 

Although PM is a rare disease, it is associated with increased morbidity and mortality due to its associated comorbid conditions, e.g., major vessels or gastrointestinal tract involvement, etc. It rarely presents in childhood and usually affects people above the age of 20 years. It is characterized by symmetrical proximal muscle weakness due to the involvement of endomysial layers of skeletal muscles versus DM, which involves the perimysial layers of muscles along with dermatological presentations.

 

PM develops due to abnormal activation of cytotoxic T lymphocytes (CD8 cells) and macrophages against muscular antigens as well as the strong extrafusal muscular expression of major histocompatibility complex 1, causing damage to the endomysium of skeletal muscles.

 

In PM, multiple small foci of inflammatory and necrotic changes and regenerative nodules can be seen on biopsy. Histopathological findings of PM show endomysial mononuclear infiltrate consisting of mostly CD8 T cells and macrophages along with necrotic myofibrils in the early stage. Late-stage changes include occluded capillaries secondary to inflammatory changes caused by endothelial damage and increased deposition of connective tissue and extracellular matrix. PM can be differentiated from IBM due to the presence of intracytoplasmic inclusion bodies in IBM and from DM due to perimysial infiltrates of CD4 cells as well as B lymphocytes. Polymyositis is a relatively challenging diagnosis due to the absence of dermatological findings when compared to DM.

 

PM is treated with a combination of different pharmacological and non-pharmacological modalities. Pharmacological treatment mainly includes corticosteroids. Prednisone and methylprednisolone are the most common corticosteroids used for Polymyositis, with a starting dose of 1 mg/kg of prednisone a day. The steroids are tapered off gradually and not withdrawn suddenly. The second-line treatment option includes using immune-modulators (methotrexate, azathioprine, and cyclosporine) in those patients who either do not respond to steroids or develop severe adverse effects due to steroids usage. Cyclophosphamide, an immune-modulator, works efficiently, especially in patients with the involvement of the pulmonary interstitium. In the case of chronic refractory Polymyositis, intravenous immunoglobulins (IVIG) can be used. Other therapies options include tacrolimus, a calcineurin inhibitor, which has proven beneficial in patients with a refractory disease with simultaneous use of prednisolone. Mycophenolate mofetil and the anti-CD20 monoclonal antibody rituximab have also been found to be useful in treating refractory cases of Polymyositis.

 

Without proper management, the morbidity and mortality from Polymyositis are high. Thus, successful diagnosis and treatment at the initial stage are important.

 

Polymyositis Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Polymyositis market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The DelveInsight Polymyositis market report gives a thorough understanding of Polymyositis by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Polymyositis in the US, Europe, and Japan.

Polymyositis Epidemiology

The Polymyositis epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the prevalent patient pool, trends, and assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Polymyositis epidemiology segmented as the Prevalent cases of Polymyositis, Gender-specific Cases of Polymyositis, and Age-specific Cases of Polymyositis. The report includes the prevalent scenario of Polymyositis symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Polymyositis Epidemiology

The epidemiology segment also provides the Polymyositis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The prevalent population of Polymyositis in the 7MM countries was estimated to be 58,913 cases in 2020.

Polymyositis Drug Chapters

The drug chapter segment of the Polymyositis report encloses the detailed analysis of Polymyositis marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps to understand the Polymyositis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

 

Polymyositis Emerging Drugs

The current pipeline is limited, consisting of only a few assets, namely, Stelara (Janssen Pharmaceutical KK), KZR-616 (Kezar Life Sciences),  Orencia (Bristol-Myers Squibb/ONO Pharma), and PF1801 (Immunoforge).

 

Stelara (Janssen Pharmaceutical KK) is a human interleukin-12 and a -23 antagonist indicated for the treatment of adult patients with moderate to severe plaque psoriasis (Ps), active PsA, and moderately to severely active Crohn’s disease (CD). The drug binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T cell differentiation and activation. It is currently being evaluated in Phase III study to treat PM.

 

KZR-616 (Kezar Life Sciences) is the first-in-class small molecule drug. As a selective inhibitor of the immunoproteasome, KZR-616 has demonstrated broad immunomodulatory activity and has the potential to be a necessary new treatment for patients with autoimmune disorders. The drug is being evaluated in Phase II PRESIDIO study to treat PM. The study achieved target enrollment in August 2021, and top-line results are anticipated in the second quarter of 2022. In addition, Kezar is planning registrational studies of KZR-616 in inflammatory myositis based on high unmet need, strong preclinical data, demonstration of immunoproteasome activity in inflamed muscle, and data from the MISSION trial demonstrating that KZR-616 is an active agent disease.

Products detail in the report…

Polymyositis Market Outlook

The Polymyositis market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Polymyositis market trends by analyzing the impact of current therapies on the market, unmet needs,  and demand for better technology.

 

This segment gives a thorough detail of Polymyositis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Polymyositis market in the 7MM is expected to change in the study period 2018–2030.

 

The current treatment of PM consists of first-line high-dose steroids and various conventional second-line treatments. Steroid-sparing agents like Methotrexate (MTX) are the second-line treatment if steroid therapy fails. Azathioprine and cyclophosphamide also fall into this category. Cyclosporine, a specific calcineurin inhibitor, has been reported as almost as effective as MTX. Tacrolimus, also a calcineurin inhibitor, and mycophenolate mofetil could be additional alternatives for the treatment. Several clinical trials have demonstrated that high-dose intravenous immunoglobulin and Rituximab are promising.  However, a significant portion of patients does not respond to any therapy. Thus, considering the high unmet needs in the treatment, novel treatment is warranted to cater to patients with PM.

 

Key Findings

This section includes a glimpse of the Polymyositis market in the 7MM. The market size of Polymyositis in the seven major markets was USD 88.7 million in 2020.

 

The United States: Market Outlook

This section provides the total Polymyositis market size and market size by therapies of Polymyositis in the United States.

 

The United States accounts for the highest market size of Polymyositis compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

Corticosteroids and immunosuppressive agents are the mainstays of therapy for PM. The principal goals of therapy are to improve strength and improve physical functioning. Many patients require treatment for several years, and the 5-year survival rate for treated patients is in the order of 95%. Up to one-third of PM, patients may be left with some degree of residual muscle weakness.

 

Corticosteroids like prednisone are the first line of therapy for PM. The usual starting dose is 1 mg/kg/day of prednisone or its equivalent. This dose is usually maintained for the first 6–8 weeks. The response to therapy should be assessed every 2–4 weeks by monitoring the proximal muscle strength, muscle enzyme levels, and patient functionality. Muscle strength and functional measures are better indicators of improvement than muscle enzyme levels. After the initial 6–8 weeks, a slow taper of steroids should begin. The goal is to taper steroids off or the lowest possible effective dose over 9–12 months.

 

A significant proportion of patients cannot be managed with steroids alone, either because of side effects, poor disease control, or both. Many rheumatologists start a steroid-sparing immunosuppressive agent when steroids are initiated, while others reserve these agents for patients who have failed corticosteroid monotherapy.

 

To counter the ’market’s current unmet needs and provide better treatment options, several companies are working aggressively to develop new therapies with a novel mechanism of action.

 

EU-5 Countries: Market Outlook

The total Polymyositis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

 

Japan Market Outlook

The total Polymyositis market size and market size by therapies of Polymyositis in Japan are also mentioned.

Polymyositis Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Polymyositis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Polymyositis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses Polymyositis’s key players involved in developing targeted therapeutics.

 

Major players include Kezar Life Sciences, Janssen Pharmaceutical KK, whose key products are expected to get launched in the US market by 20XX.

 

Pipeline Development Activities

The report covers collaborations, acquisition, merger, licensing, and patent details for Polymyositis emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Polymyositis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Polymyositis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Polymyositis market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Polymyositis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Polymyositis epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Polymyositis is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Polymyositis market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Polymyositis market.

Report Highlights

  • In the coming years, the Polymyositis market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Polymyositis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Polymyositis. The launch of emerging therapies will significantly impact the Polymyositis market.
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Polymyositis.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Polymyositis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Polymyositis Pipeline Analysis
  • Polymyositis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Polymyositis Report Key Strengths

  • 10-years Forecast
  • 7MM Coverage
  • Polymyositis Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Polymyositis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

Key Questions

Market Insights:

  • What was the Polymyositis Market share (%) distribution in 2018, and how would it look in 2030?
  • What would be the Polymyositis total market size and market size by therapies across the 7MM during the forecast period (2018–2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Polymyositis market Size during the forecast period (2018–2030)?
  • At what CAGR is the Polymyositis market expected to grow in the 7MM forecast period (2018–2030)?
  • What would be the Polymyositis market outlook across the 7MM during the forecast period (2018–2030)?
  • What would be the Polymyositis market growth till 2030, and what will be the resultant market Size in the year 2030?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Polymyositis?
  • What is the historical Polymyositis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Polymyositis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Polymyositis?
  • Out of all 7MM countries, which country would have the highest prevalence of Polymyositis during the forecast period (2018–2030)?
  • At what CAGR is the population expected to grow in the 7MM forecast period (2018–2030)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Polymyositis?
  • What are the current treatment guidelines for treating Polymyositis in the USA, Europe, and Japan?
  • What are the Polymyositis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Polymyositis?
  • How many therapies are developed by each company for the treatment of Polymyositis?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Polymyositis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polymyositis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Polymyositis and its status?
  • What have key designations been granted for the emerging therapies for Polymyositis?
  • What are the global historical and forecasted markets for Polymyositis?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Polymyositis market
  • Organize sales and marketing efforts by identifying the best opportunities for Polymyositis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Polymyositis market.
  • To understand the future market competition in the Polymyositis market.

1. Key Insights

2. Report Introduction

3. Polymyositis Market Overview at a Glance

3.1. Market Share (%) of Polymyositis by Therapies in 2018

3.2. Market Share (%) of Polymyositis by Therapies in 2030

4. Executive Summary of Polymyositis

5. Polymyositis: Disease Background and Overview

5.1. Introduction

5.2. Signs and Symptoms

5.3. Etiology

5.4. Pathophysiology

5.5. Diagnosis

6. Differential Diagnosis

6.1. Treatment

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7MM Total Prevalence of Polymyositis

7.3. Epidemiology of Polymyositis

7.4. The United States

7.4.1. Prevalence of Polymyositis in the United States

7.4.2. Gender-specific cases of Polymyositis in the United States

7.4.3. Age-specific cases of Polymyositis in the United States

7.5. EU5

7.5.1. Total Prevalence of Polymyositis in EU5

7.5.2. Germany

7.5.2.1. Gender-specific cases of Polymyositis in Germany

7.5.2.2. Age-specific cases of Polymyositis in Germany

7.5.3. France

7.5.3.1. Gender-specific cases of Polymyositis in France

7.5.3.2. Age-specific cases of Polymyositis in France

7.5.4. Italy

7.5.4.1. Gender-specific cases of Polymyositis in Italy

7.5.4.2. Age-specific cases of Polymyositis in Italy

7.5.5. Spain

7.5.5.1. Gender-specific cases of Polymyositis in Spain

7.5.5.2. Age-specific cases of Polymyositis in Spain

7.5.6. The United Kingdom

7.5.6.1. Gender-specific cases of Polymyositis in the United Kingdom

7.5.6.2. Age-specific cases of Polymyositis in the United Kingdom

7.6. Japan

7.6.1. Prevalence of Polymyositis in Japan

7.6.2. Gender-specific cases of Polymyositis in Japan

7.6.3. Age-specific cases of Polymyositis in Japan

8. Patient Journey

9. Marketed Therapy

9.1. Acthar Gel (corticotropin): Boehringer Ingelheim Pharmaceuticals

9.1.1. Product Description

9.1.2. Safety and Efficacy

9.1.3. Side Effects

9.1.4. Product Profile

9.2. Venoglobulin: Mitsubishi Tanabe Pharma

9.2.1. Product Description

9.2.2. Regulatory Milestones

9.2.3. Product Profile

10. Emerging Therapies

10.1. Key Cross Competition

10.2. Stelara (Ustekinumab): Janssen Pharmaceutical KK.

10.2.1. Product Description

10.2.2. Clinical Development

10.2.3. Clinical trials information

10.2.4. Product Profile

10.2.5. Analysts’ Views

10.3. KZR-616: Kezar Life Sciences

10.3.1. Product Description

10.3.2. Other Development Activities

10.3.3. Clinical Development

10.3.4. Clinical trials information

10.3.5. Product Profile

10.3.6. Analysts’ Views

11. Other Assets

11.1. Key Competitors: Other Assets

11.2. Orencia (Abatacept): Bristol-Myers Squibb/ ONO Pharma

11.2.1. Product Description

11.2.2. Other Development Activities

11.2.3. Clinical Development

11.2.4. Clinical trials information

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.3. Daxdilimab (HZN-7734/MEDI7734/ VIB7734): Horizon Therapeutics

11.3.1. Product Description

11.3.2. Other Development Activities

11.3.3. Clinical Development

11.3.4. Clinical trials information

11.3.5. Product Profile

11.4. PF1801: Immunoforge

11.4.1. Product Description

11.4.2. Other Development Activity

11.4.3. Product Profile

11.5. Umbilical Cord Lining Stem Cells: Restem, LLC.

11.5.1. Product Description

11.5.2. Clinical Development

11.5.3. Clinical Trials Information

11.5.4. Product Profile

11.6. Olumiant (Baricitinib):  Eli Lilly and Company

11.6.1. Product Description

11.6.2. Clinical Development

11.6.3. Clinical trials information

11.6.4. Product Profile

12. Polymytosis: Seven Major Market Analysis

12.1. Key Findings

12.2. Market Size of Polymyositis in 7MM

12.3. Market Outlook

12.4. The United States Market Size

12.4.1. Total Market Size of Polymyositis in the United States

12.4.2. Market Size of Polymyositis by Therapies in the United States

12.5. Market Size of Polymyositis in EU-5

12.5.1. Market Size of Polymyositis by Therapies in Germany

12.5.2. Market Size of Polymyositis by Therapies in France

12.5.3. Market Size of Polymyositis by Therapies in Italy

12.5.4. Market Size of Polymyositis by Therapies in Spain

12.5.5. Market Size of Polymyositis by Therapies in the United Kingdom

12.6. Japan Market Size

12.6.1. Total Market Size of Polymyositis in Japan

12.6.2. Market Size of Polymyositis by Therapies in Japan

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access

17. Appendix

17.1. Report Methodology

17.2. Bibliography

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of Polymyositis, Epidemiology, and Key Events (2018–2030)

Table 2: Bohan and Peter criteria for Polymyositis

Table 3: Autoantibodies in PM

Table 4: Therapeutic regimens for PM

Table 5: Prevalence of Polymyositis in the 7MM (2018–2030)

Table 6: Prevalence of Polymyositis in the United States (2018–2030)

Table 7: Gender-specific cases of Polymyositis in the United States (2018–2030)

Table 8: Age-specific cases of Polymyositis in the United States (2018–2030)

Table 9: Prevalence of Polymyositis in EU5 (2018–2030)

Table 10: Gender-specific cases of Polymyositis in Germany (2018–2030)

Table 11: Age-specific cases of Polymyositis in Germany (2018–2030)

Table 12: Gender-specific cases of Polymyositis in France (2018–2030)

Table 13: Age-specific cases of Polymyositis in France (2018–2030)

Table 14: Gender-specific cases of Polymyositis in Italy (2018–2030)

Table 15: Age-specific cases of Polymyositis in Italy (2018–2030)

Table 16: Gender-specific cases of Polymyositis in Spain (2018–2030)

Table 17: Age-specific cases of Polymyositis in Spain (2018–2030)

Table 18: Gender-specific cases of Polymyositis in the United Kingdom (2018–2030)

Table 19: Age-specific cases of Polymyositis in the United Kingdom (2018–2030)

Table 20: Prevalence of Polymyositis in Japan (2018–2030)

Table 21: Gender-specific cases of Polymyositis in Japan (2018–2030)

Table 22: Age-specific cases of Polymyositis in Japan (2018–2030)

Table 23: Key Competitors: Emerging Therapies

Table 24: Stelara (ustekinumab), Clinical Trial Description, 2021

Table 25: KZR-616, Clinical Trial Description, 2021

Table 26: Orencia (Abatacept), Clinical Trial Description, 2021

Table 28: Daxdilimab (HZN-7734), Clinical Trial Description, 2021

Table 29: Umbilical Cord Lining Stem Cells, Clinical Trial Description, 2021

Table 30: Olumiant (Baricitinib), Clinical Trial Description, 2021

Table 31: Seven Major Market Size of Polymyositis in USD Million (2018–2030)

Table 32: Market Size of Polymyositis in the United States in USD Million (2018–2030)

Table 33: The US Market Size of Polymyositis by Therapies in USD Million (2018–2030)

Table 34: EU5 Market Size of Polymyositis in USD Million (2018–2030)

Table 35: Market Size of Polymyositis by Therapies in Germany in USD Million (2018–2030)

Table 36: Market Size of Polymyositis by Therapies in France in USD Million (2018–2030)

Table 37: Market Size of Polymyositis by Therapies in Italy in USD Million (2018–2030)

Table 38: Market Size of Polymyositis by Therapies in Spain in USD Million (2018–2030)

Table 39: Market Size of Polymyositis by Therapies in the United Kingdom in USD Million (2018–2030)

Table 40: Market Size of Polymyositis in Japan in USD Million (2018–2030)

Table 41: Market Size of Polymyositis by Therapies in Japan in USD Million (2018–2030)

List of Figures

Figure 1: Pathways involved in the pathophysiology of PM

Figure 2: Potential immune mechanisms in myositis pathogenesis

Figure 3: Immune-related potential therapeutic targets in myositis

Figure 4: Diagnostic Tests for PM

Figure 5: Diagnostic Algorithm for PM

Figure 6: Overview of treatment essentials in PM

Figure 7: Total Prevalent Population of Polymyositis in 7MM (2018–2030)

Figure 8: Prevalence of Polymyositis in the United States (2018–2030)

Figure 9: Gender-specific cases of Polymyositis in the United States (2018–2030)

Figure 10: Age-specific cases of Polymyositis in the United States (2018–2030)

Figure 11: Total Prevalent Population of Polymyositis in EU5 (2018–2030)

Figure 12: Gender-specific cases of Polymyositis in Germany (2018–2030)

Figure 13: Age-specific cases of Polymyositis in Germany (2018–2030)

Figure 14: Gender-specific cases of Polymyositis in France (2018–2030)

Figure 15: Age-specific cases of Polymyositis in France (2018–2030)

Figure 16: Gender-specific cases of Polymyositis in Italy (2018–2030)

Figure 17: Age-specific cases of Polymyositis in Italy (2018–2030)

Figure 18: Gender-specific cases of Polymyositis in Spain (2018–2030)

Figure 19: Age-specific cases of Polymyositis in Spain (2018–2030)

Figure 20: Gender-specific cases of Polymyositis in the United Kingdom (2018–2030)

Figure 21: Age-specific cases of Polymyositis in the United Kingdom (2018–2030)

Figure 22: Prevalence of Polymyositis in Japan (2018–2030)

Figure 23: Gender-specific cases of Polymyositis in Japan (2018–2030)

Figure 24: Age-specific cases of Polymyositis in Japan (2018–2030)

Figure 25: Seven Major Market Size of Polymyositis in USD Million (2018–2030)

Figure 26: Market Size of Polymyositis in the United States in USD Million (2018–2030)

Figure 27: Market Size of Polymyositis in the United States by Therapies (2018–2030)

Figure 28: EU5 Market Size of Polymyositis in USD Million (2018–2030)

Figure 29: Market Size of Polymyositis in Germany by Therapies (2018–2030)

Figure 30: Market Size of Polymyositis in France by Therapies (2018–2030)

Figure 31: Market Size of Polymyositis in Italy by Therapies (2018–2030)

Figure 32: Market Size of Polymyositis in Spain by Therapies (2018–2030)

Figure 33: Market Size of Polymyositis in the United Kingdom by Therapies (2018–2030)

Figure 34: Market Size of Polymyositis in Japan in USD Million (2018–2030)

Figure 35: Market Size of Polymyositis in Japan by Therapies (2018–2030)

Boehringer Ingelheim Pharmaceuticals
Mitsubishi Tanabe Pharma
Janssen Pharmaceutical
Kezar Life Sciences
Bristol-Myers Squibb
ONO Pharma
Horizon Therapeutics
Immunoforge
Restem, LLC.
Eli Lilly and Company

 

Forward to Friend

Need A Quote